What's Going On With Revolution Medicines Stock?

Revolution Medicines, Inc.  RVMD shares are trading higher Wednesday. The company announced the publication of several peer-reviewed research papers earlier in the week. 

The Details:

Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. 

The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. 

“The research summarized in our Cancer Discovery paper, combined with the preliminary RMC-6236 clinical data presented in late 2023, provide us and our investigators with the confidence to advance and expand our RMC-6236 clinical development program,” said Steve Kelsey, M.D., president, research and development of Revolution Medicines.

According to data from Benzinga Pro, Revolution Medicines shares are trading above the stock’s 50-day moving average of $30.53 and set a new intraday 52-week high of $37.50 Wednesday. 

Related News: What’s Going On With Chinese EV Stocks Nio And XPeng?

Is RVMD A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Revolution Medicines‘ page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Revolution Medicines does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 110.75%, you'll need to buy a share of Lufax Holding by June 4. Once done, you can expect to receive a nominal payout of $2.37 on June 8.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Revolution Medicines will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

RVMD Price Action: According to Benzinga Pro, Revolution Medicines shares are up 9.78% at $36.22 at the time of publication Wednesday.

Image: Studio Iris from Pixabay